Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jane Tramontana

Pulmonary Disease Leesburg, VA Medical Doctor

NPI 1871034595 CMS profile 2876545

19455 Deerfield Ave, Suite 206, Leesburg, VA 20176

Open in the dashboard

General payments

$7,819

328 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jane Tramontana of Leesburg, VA is reported in the CMS Open Payments database as having received $7,819 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,290 92
2024 General $1,986 72
2023 General $1,792 80
2020 General $219 13
2019 General $1,532 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Tramontana
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jane Tramontana were reported at $2,290. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jane Tramontana Pulmonary Disease median Middle half National median
2019 $1,532 $377 $109–$1,340 $163
2020 $219 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $1,792 $419 $114–$1,659 $160
2024 $1,986 $476 $123–$1,818 $164
2025 $2,290 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,064 86 payments
  2. GlaxoSmithKline, LLC. $1,484 70 payments
  3. Regeneron Healthcare Solutions, Inc. $877 35 payments
  4. Genzyme Corporation $523 19 payments
  5. Inspire Medical Systems, Inc. $339 4 payments
  6. Electromed, Inc. $304 18 payments
  7. Mylan Specialty L.P. $280 14 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $273 14 payments
  9. Harmony Biosciences LLC $213 7 payments
  10. Grifols USA, LLC $192 9 payments
  11. Other $1,269 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,628 325 payments
  2. Education $192 3 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $622 24 payments
  2. DUPIXENT Immunology $583 19 payments
  3. TRELEGY ELLIPTA $571 25 payments
  4. FASENRA $562 24 payments
  5. NUCALA Immunology $540 23 payments
  6. AIRSUPRA $517 21 payments
  7. BREZTRI $440 16 payments
  8. INSPIRE $339 4 payments
  9. TEZSPIRE $265 12 payments
  10. NUCALA Respiratory $265 12 payments
  11. Other $3,658 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,334

Median for Pulmonary Disease: 936

Drug cost

$454,442

Median for Pulmonary Disease: $487,987

Branded share of claims

72.9%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 181 $133,436
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 130 $85,846
Breo Ellipta Fluticasone/Vilanterol Brand 123 $63,773
Spiriva Respimat Tiotropium Bromide Brand 57 $44,041
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 68 $37,166
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 48 $29,604
Incruse Ellipta Umeclidinium Bromide Brand 45 $16,887
Symbicort Budesonide/Formoterol Fumarate Brand 42 $11,880
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 38 $6,285
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 13 $5,560

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$139,340

Medicare's payments for the services billed

Medicare patients

507

Average age 77

Services billed

1,834

308 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
COPD 57%
Ischemic heart disease 45%
Heart failure 35%
Diabetes 33%
Chronic kidney disease 33%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $232
  • Regeneron Healthcare Solutions, Inc. $222
  • SANOFI-AVENTIS U.S. LLC $80
$534 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $355
$355 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $198
$198 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $125
$125 130 —
YUPELRI
  • Mylan Specialty L.P. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record